US · BDTX
Black Diamond Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Cambridge, MA 02142
- Website
- blackdiamondtherapeutics.com
Price · as of 2024-12-31
$2.60
Market cap 140.73M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $29.00 | ||||
| 2020 | $26.49 | ||||
| 2021 | $2.78 | ||||
| 2022 | $1.35 | ||||
| 2023 | $4.06 | ||||
| 2024 | $1.88 |
AI valuation
Our deep-learning model estimates Black Diamond Therapeutics, Inc.'s (BDTX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $2.60
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BDTX | Black Diamond Therapeutic… | $2.60 | 140.73M | — | — | — | — | -1.48 | 1.24 | — | -0.35 | — | 1.24 | 0.00% | — | — | -69.67% | -898.81% | -49.55% | 0.27 | — | 4.92 | 4.79 | 0.18 | -3245.00% | — | -666.00% | -60.22% | -3.03 | -710.82% | 0.00% | 0.00% | 0.00% | -0.34 | -0.43 | — | -5.31 |
| AARD | Aardvark Therapeutics, In… | $12.49 | 271.95M | — | — | — | — | -6.35 | -2.39 | — | -2.56 | -3.45 | -2.39 | 0.00% | — | — | 46.03% | 26.47% | -46.77% | -0.01 | — | 15.05 | 14.95 | 2.69 | 18393.00% | — | 21243.00% | -13.91% | -3.67 | 21.14% | 0.00% | 0.00% | 39.22% | -2.54 | -3.18 | — | -0.36 |
| ABEO | Abeona Therapeutics Inc. | $5.12 | 277.46M | +447% | — | — | — | -3.32 | 4.81 | — | -2.42 | — | 4.81 | 0.00% | — | — | -216.57% | 205.01% | -73.71% | 0.52 | -15.26 | 6.08 | 5.99 | 0.01 | -3874.00% | -10000.00% | 5656.00% | -27.60% | -3.38 | 186.65% | 0.00% | 0.00% | 0.00% | -2.14 | -2.35 | — | -9.51 |
| AVTX | Avalo Therapeutics, Inc. | $17.50 | 197.65M | -16% | -59% | — | +1,518% | -1.80 | 0.47 | 143.03 | 1.04 | — | 0.51 | 182.99% | -15535.60% | -7965.76% | -50.06% | 26350.77% | -40.91% | 0.00 | — | 19.96 | 19.42 | 1.96 | -9713.00% | -7708.00% | 5908.00% | -77.77% | -7.05 | 18867.69% | 0.00% | 0.00% | 201.50% | 1.03 | 1.45 | -160.77 | -1.75 |
| CRBU | Caribou Biosciences, Inc. | $1.90 | 177.59M | +1,241% | -57% | — | +5,094% | -0.70 | 0.41 | 10.48 | 0.48 | -3.59 | 0.41 | 60.71% | -1667.16% | -1491.95% | -47.99% | -243.96% | -40.00% | 0.10 | — | 7.16 | 6.94 | -0.06 | 1957.00% | -7101.00% | 3794.00% | -138.12% | -4.51 | -211.89% | 0.00% | 0.00% | 0.00% | 0.47 | 0.54 | -7.83 | -1.96 |
| ENTA | Enanta Pharmaceuticals, I… | $14.30 | 332M | +189% | -59% | — | — | -3.80 | 4.81 | 4.77 | -4.57 | — | 4.81 | 92.98% | -130.65% | -125.36% | -84.63% | -91.13% | -24.91% | 3.11 | -11.11 | 4.21 | 4.03 | -2.38 | -2993.00% | -342.00% | -6674.00% | -10.33% | -0.40 | -35.04% | 0.00% | 0.00% | 6.44% | -3.79 | -10.06 | 4.96 | -1.26 |
| FENC | Fennec Pharmaceuticals In… | $8.49 | 233.9M | +1,836% | +110,254% | — | — | -430.69 | -31.98 | 3.95 | 37.62 | — | -31.98 | 93.30% | 5.40% | -0.92% | 4.98% | -72.31% | -1.21% | -3.29 | 0.63 | 6.38 | 5.71 | -1.52 | -9733.00% | 12369.00% | -25738.00% | 14.37% | 3.90 | -759.68% | 0.00% | 0.00% | 13.40% | 70.28 | 6.69 | 3.80 | -2.39 |
| FHTX | Foghorn Therapeutics Inc. | $5.68 | 332.74M | +360% | -68% | — | +572% | -2.86 | -5.45 | 10.98 | -0.43 | — | -5.45 | 100.00% | -454.31% | -383.24% | 141.17% | 39.62% | -30.40% | -0.82 | — | 3.73 | 3.64 | 0.19 | -3248.00% | -3383.00% | -1510.00% | -40.83% | -1.50 | 39.09% | 0.00% | 0.00% | 0.00% | -0.40 | -0.41 | 1.84 | -2.64 |
| IMRX | Immuneering Corporation | $4.99 | 181.15M | — | — | — | — | -0.75 | 1.10 | — | -0.21 | -8.77 | 1.33 | 0.00% | — | — | -92.51% | -682.42% | -78.61% | 0.10 | — | 5.28 | 4.82 | 0.50 | 851.00% | — | 1171.00% | -120.87% | -7.33 | -586.70% | 0.00% | 0.00% | 0.00% | -0.21 | -0.25 | — | -6.82 |
| IVA | Inventiva S.A. | $6.49 | 337.36M | +349% | -81% | — | +2,278% | -0.75 | -1.30 | 15.02 | -0.58 | -1.64 | -1.29 | 100.00% | -1060.64% | -2002.74% | 265.67% | 114.26% | -195.42% | -0.51 | -8.01 | 0.92 | 0.90 | 0.25 | 4568.00% | -4737.00% | 500.00% | -62.45% | -0.71 | 101.03% | 0.00% | 0.00% | 38.23% | -0.98 | -1.11 | 10.43 | -4.52 |
| TNYA | Tenaya Therapeutics, Inc. | $0.56 | 93.6M | — | — | — | — | -0.35 | 0.42 | — | 0.09 | — | 0.42 | 0.00% | — | — | -95.69% | -251.45% | -76.52% | 0.15 | — | 4.22 | 3.85 | -0.09 | -2202.00% | — | -1141.00% | -237.15% | -5.67 | -198.49% | 0.00% | 0.00% | 0.00% | 0.08 | 0.10 | — | -7.83 |
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
- CEO
- Mark A. Velleca
- Employees
- 24
- Beta
- 3.36
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $2.60) − 1 = — (DCF, example).